Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,632 signal articles · 28 in last 24h · 155,714 total before filter · latest 1h ago
28last 24h
849last 7d
142● bullish (7d)
89● bearish (7d)
214publishers
AllMacro196Earnings106M&A122Regulatory20Product21Analyst19
Sentiment:bullishneutralbearishshow all (incl. clickbait)
Investing.com34d agoneutral
Citi expects Nvidia stock to trade higher post earnings

Investing.com -- Nvidia is expected to report stronger-than-anticipated quarterly sales next week, with Citi raising its revenue forecasts on improved shipments of AI networking components and a continued ramp-up of the company's Blackwell chips.

Hype for Moderna’s Cancer Vaccine Is Running Ahead of the Math
The Wall Street Journal34d agoneutral
Hype for Moderna’s Cancer Vaccine Is Running Ahead of the Math

Moderna has always been a stock driven by narrative extremes. During the pandemic, it traded as if mRNA would transform medicine overnight, with its market capitalization peaking near $200 billion. Shares exploded 177% in a single session on Wednesday—the largest one-day surge for an S&P 500 company in over two decades—after Moderna and partner Merck reported successful late-stage trial results for their personalized mRNA melanoma vaccine.

Investing.com34d agoneutral
Could Canada fully supply the U.S. with aluminium?

Investing.com -- Canada could not fully meet U.S. aluminium import requirements, even if it redirected all domestic production south of the border, Morgan Stanley said in a research note examining potential tariff relief.

Is Cigna Group (CI) Still Cheap Based On Its Earnings?
Simply Wall St.34d agoneutral
Is Cigna Group (CI) Still Cheap Based On Its Earnings?

Cigna Group stock has delivered a 44.4% gain over the past five years, yet the broader valuation checks still suggest the shares screen as undervalued at the recent price of US$277.51. With shorter term returns weaker, investors are left weighing a mixed share price history against a still supportive valuation read. Over five years, Cigna Group has returned 44.4%, which points to solid long term wealth creation despite more recent share price softness. Expectations for the company to keep...